- Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?
[作者:Papeo, G; Forte, B; Orsini, P; Perrera, C; Posteri, H; Scolaro, A; Montagnoli, A,期刊:Expert Opinion on Therapeutic Patents, 页码:1377-1400 , 文章类型: Review,,卷期:2009年19-10]
- Background: During the last few years an increasing number of poly(ADP-ribose) polymerase (PARP) inhibitors have been appearing in the context of cancer therapy. This is mainly due to a better knowledge of the best-chara...
- GPR119 agonists for the treatment of type 2 diabetes
[作者:Jones, RM; Leonard, JN; Buzard, DJ; Lehmann, J,期刊:Expert Opinion on Therapeutic Patents, 页码:1339-1359 , 文章类型: Review,,卷期:2009年19-10]
- Background: Diabetes is a chronic disease that occurs when the pancreas does not produce enough insulin, or when the body cannot effectively use the insulin it produces. Hyperglycemia, or raised blood sugar, is a common ...
- Modulation of neuropeptide Y receptors for the treatment of obesity
[作者:Sato, N; Ogino, Y; Mashiko, S; Ando, M,期刊:Expert Opinion on Therapeutic Patents, 页码:1401-1415 , 文章类型: Review,,卷期:2009年19-10]
- Background: Neuropeptide Y (NPY) has been demonstrated to have critical roles in the physiological control of appetite and energy homeostasis through NPY Y1, Y2, Y4 and Y5 receptors. A number of synthetic ligands for NPY...
|